Site Logo

Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.

A Large, Long-Term Disease Registry in Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) Maximizes Patient Enrollment While Minimizing Site Burden

UBC is currently managing an AML / MDS disease registry for a leading biopharmaceutical client with 200 sites working toward an enrollment target of 2,100 patients across three cohorts. The study has been ongoing for eight years to provide insights from current and evolving treatment regimens, and the impact on prognosis and health-related quality of life.

UBC has developed strategies for identifying and efficiently activating productive clinical sites allowing for the collection of high-quality data that will support those unanswered questions for our sponsors.

Download our case study today to hear how the management of our clients disease registry and the strategies we have implemented over the eight year program, best fits the needs of the patients while improving the program’s productivity.

“Thanks to your compassion and perseverance, we are so much closer to understanding and dissecting the needs of our patients, the evolution of the disease, and how we can better serve and treat those affected by it.”

Sr. Study Manager, US Medical Affairs

Rare Disease Registry AML MDS

To learn more about our expansive rare disease and registry solutions, head here.